Antiphospholipid syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 10: Line 10:
The mainstay of treatment in antiphospholipid syndrome(APS) is anticoagulation. The choice of anticoagulant is heparin, which is given in overlap with warfarin. In cases where warfarin is contraindicated such as pregnancy, low molecular weight heparin (LMWH) is used.
The mainstay of treatment in antiphospholipid syndrome(APS) is anticoagulation. The choice of anticoagulant is heparin, which is given in overlap with warfarin. In cases where warfarin is contraindicated such as pregnancy, low molecular weight heparin (LMWH) is used.


===Treatment of acute thromosis in APS===
===1.Treatment of acute thromosis in APS===
*The choice of treatment for acute thrombosis in APS is low molecular weight heparin (LMWH).  
*The choice of treatment for acute thrombosis in APS is low molecular weight heparin (LMWH).  
*It is overlapped with warfarin for a minimum of 4-5 days.
*It is overlapped with warfarin for a minimum of 4-5 days.
*It is continued as long as the International normalized ratio (INR) is in the therapeutic range that is 2-3.
*It is continued as long as the International normalized ratio (INR) is in the therapeutic range that is 2-3.


===Treatment of recurrent thrombosis despite anticoagulation===
===2.Treatment of recurrent thrombosis despite anticoagulation===
===Management of noncriteria manifestations===
===3.Management of noncriteria manifestations===


===Anticoagulation in pregnancy===
===4.Anticoagulation in pregnancy===
*During pregnancy, [[low molecular weight heparin]] and low-dose [[aspirin]] are used to avoid warfarin's teratogenicity.
*During pregnancy, [[low molecular weight heparin]] and low-dose [[aspirin]] are used to avoid warfarin's teratogenicity.
*The therapy is initiated at the beginning of pregnancy and continued until the time of delivery.
*The therapy is initiated at the beginning of pregnancy and continued until the time of delivery.
Line 26: Line 26:
*Intravenous immunoglobulin(IgG) and corticosteroids are used for patients with refractory cases in pregnancy.
*Intravenous immunoglobulin(IgG) and corticosteroids are used for patients with refractory cases in pregnancy.


=== Limited role of alternative therapies: ===
=== 5.Limited role of alternative therapies: ===
Following alternative therapies can be used for the treatment of APS:
Following alternative therapies can be used for the treatment of APS:


Line 40: Line 40:
* Hydroxyychloroquine
* Hydroxyychloroquine


===Treatment of catastrophic antiphospholipid syndrome:===
===6.Treatment of catastrophic antiphospholipid syndrome:===
A small subset of patients develop catastrophic disease which is managed as follows:
A small subset of patients develop catastrophic disease which is managed as follows:


Line 57: Line 57:


==== Systemic glucocorticoids: ====
==== Systemic glucocorticoids: ====
* Preferred regimen (1): Methylprednisone 0.5-1g IV q12h for 3 days
This is followed by oral therapy with 1mg/kg of prednisone per day.


==== Plasma exchange: ====
==== Plasma exchange or IVIG: ====


==References==
==References==

Revision as of 16:37, 6 April 2018

Antiphospholipid syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Antiphospholipid syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Antiphospholipid syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Antiphospholipid syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Antiphospholipid syndrome medical therapy

CDC on Antiphospholipid syndrome medical therapy

Antiphospholipid syndrome medical therapy in the news

Blogs on Antiphospholipid syndrome medical therapy

Directions to Hospitals Treating Antiphospholipid syndrome

Risk calculators and risk factors for Antiphospholipid syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

Overview

The most important therapy for symptomatic antiphospholipid syndrome is platelet inhibition with or without anticoagulation. Platelet inhibition is often achieved with aspirin, while warfarin and heparin are the mainstays of anticoagulation. Typically, there is no indication for primary prophylaxis. Immunosuppression, the use of intravenous immunoglobulin, and plasmapheresis have also been used with modest success in patients with catastrophic antiphospholipid syndrome (APS).

Medical Therapy

General principles and choice of anticoagulation

The mainstay of treatment in antiphospholipid syndrome(APS) is anticoagulation. The choice of anticoagulant is heparin, which is given in overlap with warfarin. In cases where warfarin is contraindicated such as pregnancy, low molecular weight heparin (LMWH) is used.

1.Treatment of acute thromosis in APS

  • The choice of treatment for acute thrombosis in APS is low molecular weight heparin (LMWH).
  • It is overlapped with warfarin for a minimum of 4-5 days.
  • It is continued as long as the International normalized ratio (INR) is in the therapeutic range that is 2-3.

2.Treatment of recurrent thrombosis despite anticoagulation

3.Management of noncriteria manifestations

4.Anticoagulation in pregnancy

  • During pregnancy, low molecular weight heparin and low-dose aspirin are used to avoid warfarin's teratogenicity.
  • The therapy is initiated at the beginning of pregnancy and continued until the time of delivery.
  • Women with recurrent miscarriage are often advised to take low dose aspirin and to start low molecular weight heparin treatment after missing a menstrual cycle.
  • For women with previous history of clots, higher dose of low molecular weight heparin is used.

Treatment of refractory cases in pregnancy

  • Intravenous immunoglobulin(IgG) and corticosteroids are used for patients with refractory cases in pregnancy.

5.Limited role of alternative therapies:

Following alternative therapies can be used for the treatment of APS:

Direct oral anticoagulants:

The rationale behind using direct oral anticoagulants such as dabigatran, apixaban or rivaroxaban is as follows:

  • They dont require laboratory monitoring of PT/aPTT.
  • They have lower risk of bleeding.
  • They are useful for patients who cannot tolerate warfarin.

Immunomodulatory agents:

Immunomodulatory agents are proposed for the use of antiphospholipid syndrome as it an autoimmune disease. The following drugs are preferred:

  • Rituximab
  • Hydroxyychloroquine

6.Treatment of catastrophic antiphospholipid syndrome:

A small subset of patients develop catastrophic disease which is managed as follows:

Pearls of management:

Early diagnosis and timely management with adressing the thrombotic events and suppressing the cytokine cascade is essential for the treatment.

Approach to treatment:

The steps of managing catastrophic APS are as follows:

Antibiotics:

  • Identify the underlying infection and administer appropriate antibiotics accordingly.

Anticoagualtion:

  • Anticoagulate with heparin in the acute setting.
  • In hemodynamically stable patients and no evidence of bleeding, oral anticoagulant such as warfarin can be used.

Systemic glucocorticoids:

  • Preferred regimen (1): Methylprednisone 0.5-1g IV q12h for 3 days

This is followed by oral therapy with 1mg/kg of prednisone per day.

Plasma exchange or IVIG:

References

Template:WH Template:WS